EUVIMEDOpdag EUVIMED
Crossref

Systematic Optimization of Activity-Based Protein Profiling for Identification of Polysorbate-Degradative Enzymes in Biotherapeutic Drug Substance down to 10 ppb

Taku Tsukidate iD, Anita P Liu, Shannon Rivera iD, Alyssa Q Stiving iD, Jonathan Welch, Xuanwen Li iD

Journal of the American Society for Mass Spectrometry · 2024

DOI: 10.1021/jasms.4c00387 ↗

At a glance

Journal article in Journal of the American Society for Mass Spectrometry, 2024. Written by Taku Tsukidate and 5 co-authors. Institution: Analytical Research & Development Mass Spectrometry, Merck & Co., Inc., 126 East Lincoln Avenue, Rahway, New Jersey 07065, United States. Major MEDLINE topics: Polysorbates. Cited 2 times so far (Crossref); 45 references. Funded by: Merck.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

The identification and control of high-risk host cell proteins (HCPs) in biotherapeutics development are crucial for ensuring product quality and shelf life. Specifically, HCPs with hydrolase activity can cause the degradation of excipient polysorbates (PS), leading to a decrease in the shelf life of the drug product. In this study, we systematically optimized every step of an activity-based protein profiling (ABPP) workflow to identify trace amounts of active polysorbate-degradative enzymes (PSDEs) in biotherapeutic process intermediates. Evaluation of various parameters during sample preparation pinpointed the optimal pH level and fluorophosphonate (FP)-biotin concentration. Moreover, the combined use of a short liquid chromatography gradient and the fast-scanning parallel accumulation-serial fragmentation (PASEF) methodology increased sample throughput without compromising identification coverage. Tuning the trapped ion mobility spectrometry (TIMS) parameters further enhanced sensitivity. In addition, we evaluated various data acquisition modes, including PASEF combined with data-dependent acquisition (DDA PASEF), data-independent acquisition (diaPASEF), or parallel reaction monitoring (prm-PASEF). By employing the newly optimized ABPP workflow, we successfully identified PSDEs at a concentration as low as 10 ppb in a drug substance sample. Finally, the new workflow enabled us to detect a PSDE that could not be detected with the original workflow during a PS degradation root-cause investigation.

Subjects

MeSH terms (MEDLINE)

PolysorbatesIon Mobility SpectrometryTandem Mass SpectrometryChromatography, LiquidHumans

Substances

Polysorbates

Authors and institutions

  • Analytical Research & Development Mass Spectrometry, Merck & Co., Inc., 126 East Lincoln Avenue, Rahway, New Jersey 07065, United States.
  • Biologics Analytical Research & Development, Merck & Co., Inc., 126 East Lincoln Avenue, Rahway, New Jersey 07065, United States.

ORCID profiles: Taku Tsukidate, Shannon Rivera, Alyssa Q Stiving, Xuanwen Li

Funding

  • Merck

Cite

APA

Tsukidate, T., Liu, A. P., Rivera, S., Stiving, A. Q., Welch, J., & Li, X. (2024). Systematic Optimization of Activity-Based Protein Profiling for Identification of Polysorbate-Degradative Enzymes in Biotherapeutic Drug Substance down to 10 ppb. Journal of the American Society for Mass Spectrometry. https://doi.org/10.1021/jasms.4c00387

Vancouver

Tsukidate T, Liu AP, Rivera S, Stiving AQ, Welch J, Li X. Systematic Optimization of Activity-Based Protein Profiling for Identification of Polysorbate-Degradative Enzymes in Biotherapeutic Drug Substance down to 10 ppb. Journal of the American Society for Mass Spectrometry. 2024. doi:10.1021/jasms.4c00387

BibTeX
@article{Tsukidate2024,
  author = {Tsukidate, Taku and Liu, Anita P and Rivera, Shannon and Stiving, Alyssa Q and Welch, Jonathan and Li, Xuanwen},
  title = {Systematic Optimization of Activity-Based Protein Profiling for Identification of Polysorbate-Degradative Enzymes in Biotherapeutic Drug Substance down to 10 ppb},
  journal = {Journal of the American Society for Mass Spectrometry},
  year = {2024},
  doi = {10.1021/jasms.4c00387}
}
Start for free →